Pharmaceutical company
Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA) Issues related to Medicare Part B
Issues related to Medicare Part D
Coding and reimbursement for oncology drugs/biologics/biosimilars
Issues relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); the Ensuring the Value of the 340B Program Act (S. 2453), and the 340B Optimization Act (H.R. 5598)
HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
900 G Street NW, Suite 301, Washington, DC, 20001, US
STEVEN E IRIZARRY VINCENT A. ROBERTI, SR. STEVEN E IRIZARRY VINCENT A. ROBERTI, SR.